Evaluation of Tildrakizumab in the Treatment of Ocular Sequelae in Lyell syndrome

Condition studied

Ocular Sequelae in Lyell syndrome

Investigational medicinal product(s)

Eligibility

Primary endpoint

The primary efficacy endpoint of this study is the change in tear film break-up time (TBUT), measured in seconds, between baseline (Day 0) and post-treatment follow-up visits, Secondary efficacy endpoints will consist of patient-reported outcome measures designed to capture the subjective impact of treatment on ocular symptoms and vision-related quality of life.

Endpoint detail

Clinical Safety Monitoring, Patient-Reported Tolerability via DL-QI